Molecular Oncology
Volume 1, Issue 4 , Pages 395-405 , April 2008

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site

Received 27 November 2007 ,Revised 17 December 2007 ,Accepted 19 December 2007.

References 

  1. Akslen LA, Angelini S, Straume O, Bachmann IM, Molven A, Hemminki K, et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J. Invest. Dermatol. 2005;125:312–317
  2. Albino AP, Le Strange R, Oliff AI, Furth ME, Old LJ. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?. Nature. 1984;308:69–72
  3. Albino AP, Nanus DM, Mentle IR, Cordon-Cardo C, McNutt NS, Bressler J, et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene. 1989;4:1363–1374
  4. Alsina J, Gorsk DH, Germino FJ, Shih W, Lu SE, Zhang ZG, et al. Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin. Cancer Res. 2003;9:6419–6425
  5. Ball NJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. Ras mutations in human melanoma: a marker of malignant progression. J. Invest. Dermatol. 1994;102:285–290
  6. Barbacid M. Ras genes. Annu. Rev. Biochem. 1987;56:779–827
  7. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689
  8. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997–7000
  9. Carr J, Mackie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br. J. Dermatol. 1994;131:72–77
  10. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev. 1997;11:2822–2834
  11. Christensen C, Guldberg P. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. Oncogene. 2005;24:6292–6302
  12. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat. Genet. 2005;37:745–749
  13. Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 2003;63:5761–5766
  14. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 2005;353:2135–2147
  15. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 2006;24:4340–4346
  16. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, et al BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene. 2004;23:5968–5977
  17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954
  18. Daya-Grosjean L, Dumaz N, Sarasin A. The specificity of p53 mutation spectra in sunlight induced human cancers. J. Photochem. Photobiol. B. 1995;28:115–124
  19. Deichmann M, Thome M, Benner A, Naher H. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncology. 2004;66:411–419
  20. Demunter A, Ahmadian MR, Libbrecht L, Stas M, Baens M, Scheffzek K, et al. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res. 2001;61:4916–4922
  21. Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J. Invest. Dermatol. 2001;117:1483–1489
  22. Denhardt DT. Signal transduction pathways and regulation of the mammalian cell cycle: cell type-dependent integration of external signals. In:  Stein GS,  Baserga R,  Giordano A,  Denhardt DT editor. The Molecular Basis of Cell Cycle and Growth Control. New York: Wiley; 1998;p. 225–304
  23. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003;63:3883–3885
  24. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 2003;3:11–22
  25. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006;66:9483–9491
  26. Edlundh-Rose E, Egyha Zi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 2006;16:471–478
  27. Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, et al Absence of BRAF mutations in UV-protected mucosal melanomas. J. Med. Genet. 2004;41:270–272
  28. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int. J. Cancer. 1997;73:198–203
  29. van Elsas A, Zerp SF, van der Flier S, Kruse KM, Aarnoudse C, Hayward NK, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am. J. Pathol. 1996;149:883–893
  30. Eskandarpour M, Hashemi J, Kanter L, Ringborg U, Platz A, Hansson J. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J. Natl. Cancer Inst. 2003;95:790–798
  31. Eskandarpour M, Kiaii S, Zhu C, Castro J, Sakko AJ, Hansson J. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int. J. Cancer. 2005;115:65–73
  32. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol. 2006;126:154–160
  33. Gorden A, Osman I, Gai W, He D, Huang W, Davidson A, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 2003;63:3955–3957
  34. Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ, et al. Detection of B-RAF and N-RAS mutations in human melanoma. J. Am. Coll. Surg. 2005;200:362–370
  35. Grafström E, Egyhazi S, Ringborg U, Hansson J, Platz A. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin. Cancer Res. 2005;11:2991–2997
  36. Gray-Schopfer VC, Karasarides M, Hayward R, Marais R. TNFa blocks apoptosis in melanoma cells when BRAF signalling is inhibited. Cancer Res. 2007;67:122–129
  37. Hanneman KK, Cooper KD, Baron ED. Ultraviolet immunosuppression: mechanisms and consequences. Dermatol. Clin. 2006;24:19–25
  38. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003;63:5198–5202
  39. Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat. 2007;28:578–588
  40. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog. 2004;3:6
  41. Husain Z, Pathak MA, Flotte T, Wick MM. Role of ultraviolet radiation in the induction of melanocytic tumors in hairless mice following 7,12-dimethylbenz(a)anthracene application and ultraviolet irradiation. Cancer Res. 1991;51:4964–4970
  42. Ito K, Kawanishi S. Site-specific DNA damage induced by UVA radiation in the presence of endogenous photosensitizer. Biol. Chem. 1997;378:1307–1312
  43. Jafari M, Papp T, Kirchner S, Diener U, Henschler D, Burg G, et al. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. J. Cancer Res. Clin. Oncol. 1995;121:23–30
  44. Jiveskog S, Ragnarsson-Olding B, Platz A, Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol. 1998;111:757–761
  45. Joshi PC, Carraro C, Pathak MA. Involvement of reactive oxygen species in the oxidation of tyrosine and dopa to melanin and in skin tanning. Biochem. Biophys. Res. Commun. 1987;142:265–274
  46. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene. 2003;22:9217–9224
  47. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S, et al. BRAF Mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 2003;9:3362–3368
  48. Landi MT, Bauer J, Pfeiffer RM, Elder DE, Hulley B, Minghetti P, et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science. 2006;313:521–522
  49. Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J. Invest. Dermatol. 2005;125:575–579
  50. Lassacher A, Worda M, Kaddu S, Heitzer E, Legat F, Massone C, et al. T1799A BRAF mutation is common in PUVA lentigines. J. Invest. Dermatol. 2006;126:1915–1917
  51. Lupetti R, Sensi M, Mortarini R, Anichini A, Clemente C, Parmiani G. N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma. Melanoma Res. 1994;4:11–19
  52. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, et al. Determinants of BRAF mutations in primary melanomas. J. Natl. Cancer Inst. 2003;95:1878–1890
  53. Martin GS. Cell signaling and cancer. Cancer Cell. 2003;4:167–174
  54. Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 2005;10:2986–3001
  55. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720–724
  56. Nappi AJ, Vass E. Hydrogen peroxide generation associated with the oxidations of the eumelanin precursors 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid. Melanoma Res. 1996;6:341–349
  57. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin. Cancer Res. 2002;8:3468–3474
  58. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 2003;9:6483–6488
  59. Padua RA, Barrass NC, Currie GA. Activation of N-ras in a human melanoma cell line. Mol. Cell. Biol. 1985;5:582–585
  60. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell. 2001;93:53–62
  61. Pierceall WE, Kripke ML, Ananthaswamy HN. N-ras mutation in ultraviolet radiation-induced murine skin cancers. Cancer Res. 1992;52:3946–3951
  62. Platz A, Ringborg U, Brahme EM, Lagerlof B. Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res. 1994;4:169–177
  63. Platz A, Ringborg U, Grafstrom E, Hoog A, Lagerlof B. Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res. 1995;5:101–106
  64. Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell. 2002;2:5–7
  65. Pollock PM, Harper UL, Hansen KS, Yudt ML, Stark M, Robbins CM, et al High frequency of BRAF mutations in nevi. Nat. Genet. 2003;33:19–20
  66. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res. 2006;16:267–273
  67. Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int. J. Cancer. 2004;109:377–384
  68. Repasky GA, Chenette EJ, Der CJ. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. Trends Cell Biol. 2004;14:639–647
  69. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH. High BRAF mutation frequency does not characterize all melanocytic tumor types. Int. J. Cancer. 2004;111:705–710
  70. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 2003;63:756–759
  71. Sekiya T, Fushimi M, Hori H, Hirohashi S, Nishimura S, Sugimura T. Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient. Proc. Natl. Acad. Sci. USA. 1984;81:4771–4775
  72. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–430
  73. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: ‘it ain't over ‘til it's over’. Trends Cell Biol. 2000;10:147–154
  74. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin. Cancer Res. 2004;10:1753–1757
  75. Shukla VK, Hughes DC, Hughes LE, McCormick F, Padua RA. ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res. 1989;5:121–127
  76. Sivertsson A, Platz A, Hansson J, Lundeberg J. Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases. Clin. Chem. 2002;48:2164–2170
  77. Thomas NE, Alexander A, Edmiston SN, Parrish E, Millikan RC, Berwick M, et al. Tandem BRAF mutations in primary invasive melanomas. J. Invest. Dermatol. 2004;122:1245–1250
  78. Thomas NE, Berwick M, Cordeiro-Stone M. Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation?. J. Invest. Dermatol. 2006;126:1693–1696
  79. Törmänen VT, Pfeifer GP. Mapping of UV photoproducts within ras proto-oncogenes in UV-irradiated cells: correlation with mutations in human skin cancer. Oncogene. 1992;7:1729–1736
  80. Trahey M, McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science. 1987;238:542–545
  81. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 2004;122:337–341
  82. Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, et al B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS one 2. 2007;e236;http://www.plosone.org
  83. Uribe P, Wistuba II, Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am. J. Dermatopathol. 2003;25:365–370
  84. Van der Lubbe JL, Rosdorff HJ, Bos JL, Van der Eb AJ. Activation of N-ras induced by ultraviolet irradiation in vitro. Oncogene Res. 1988;3:9–20
  85. van’t Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell Biol. 1989;9:3114–3116
  86. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 2004;64:2338–2342
  87. Whitwam T, VanBrocklin MW, Russo ME, Haak PT, Bilgili D, Resau RH, et al. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene. 2007;26:4563–4570
  88. Zhang BH, Guan KL. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. Embo J. 2000;19:5429–5439

PII: S1574-7891(07)00104-4

doi: 10.1016/j.molonc.2007.12.003

Molecular Oncology
Volume 1, Issue 4 , Pages 395-405 , April 2008

Article Tools

* Image Usage & Resolution